Dr. Weiss on PD-L1 Biomarker in Lung Cancer

Jared Weiss, MD
Published: Monday, Jan 30, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

PD-L1 is a much contested biomarker in this field, Weiss explains. While its positive predictive value is beneficial, PD-L1 expression does not provide a stable negative predictor.

According to Weiss, researchers should move on from PD-L1 and start looking into different biomarkers such as mismatch repair, mutational load and mRNA expression signatures, which all show promise.
 


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

PD-L1 is a much contested biomarker in this field, Weiss explains. While its positive predictive value is beneficial, PD-L1 expression does not provide a stable negative predictor.

According to Weiss, researchers should move on from PD-L1 and start looking into different biomarkers such as mismatch repair, mutational load and mRNA expression signatures, which all show promise.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x